Cystic Fibrosis Drug Pricing Violates Human Rights According to Patients
In an unusual move, a coalition of cystic fibrosis patients and their families have filed a complaint with the United [...]
ICER Condemns Monopoly Pricing of Trikafta Despite High Marks for Efficacy
While the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis is indisputable, the Institute for Clinical and [...]
ICER Reschedules CF Meeting
The Institute for Clinical and Economic Review (ICER) has rescheduled its public meeting on cystic fibrosis treatments to Aug. 27. [...]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic [...]
ICER to CF Community: ‘We Support Actions to Receive Fair Prices’
The Institute for Clinical and Economic Review (ICER) in a letter to the cystic fibrosis community says it supports fair [...]
ICER Releases Report on Cystic Fibrosis Drugs
The Insitute for Clinical and Economic Review (ICER) released an evidence report on cystic fibrosis treatments. ICER evaluated Vertex Pharmaceuticals' [...]
ICER Releases Draft Report on Cystic Fibrosis Therapies
The Institute for Clinical and Economic Review (ICER) on Thursday, Feb. 20, released a draft evidence report on treatments for [...]
